Well-Differentiated Hand Liposarcoma with Bone Metastases Treated Successfully with Zoledronic Acid

被引:2
作者
Mystakidou, Kyriaki [1 ]
Panagiotou, Irene [1 ]
Brountzos, Elias [2 ]
Kouloulias, Vassilios [2 ]
Gouliamos, Athanasios [1 ]
机构
[1] Univ Athens, Sch Med, Pain Relief & Palliat Care Unit, Dept Radiol 1,Arete Hosp, Athens 11526, Greece
[2] Univ Athens, Sch Med, Attikon Univ Hosp, Dept Radiol 2, Athens 11526, Greece
来源
ONKOLOGIE | 2011年 / 34卷 / 12期
关键词
Liposarcomas; Bone metastases; Local recurrence; Bisphosphonates; Zoledronic acid; CONSERVATION SURGERY; MYXOID LIPOSARCOMA; LUNG-CANCER; THERAPY; BISPHOSPHONATES; SURVIVAL; SARCOMA; GROWTH; TUMORS; CELLS;
D O I
10.1159/000334551
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Well-differentiated liposarcomas of the upper extremities, such as the hand or forearm, are extremely rare and are commonly misdiagnosed and considered benign. They are frequently reported as having low metastatic potential. Case Report: We report the case of a 58-year-old man with well-differentiated hand liposarcoma and diffuse bone metastases. The patient initially presented with a tumor of the thenar eminence and was treated with marginal surgical excision and external beam irradiation. 4 months after this treatment, soft tissue local recurrence and skeletal metastases were detected. Zoledronic acid treatment (4 mg per month) was initiated, and both the tumor and the metastases regressed. The patient remains cancer-free 3.5 years after diagnosis of the metastatic disease. Conclusion: Significant metastatic disease can develop in patients with well-differentiated liposarcomas. The beneficial effect of zoledronic acid observed in this case may be related to its anticancer properties, as described in phase III trials in various tumor types.
引用
收藏
页码:706 / 709
页数:4
相关论文
共 50 条
  • [41] Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study
    Sabry, Nirmeen A.
    Habib, Emad E.
    MEDICAL ONCOLOGY, 2011, 28 (02) : 584 - 590
  • [42] Invasive Metastatic Well-Differentiated Liposarcoma to the Heart, Found in Intraoperative Transesophageal Echocardiography
    Kawakami, Junshi
    Sugiyama, Daisuke
    Terao, Erina
    Tanabe, Hiroaki
    Ueda, Kenichi
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (02)
  • [43] Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid
    Inanc, Mevlude
    Kaynar, Leylagul
    Enhos, Sukru
    Pala, Cigdem
    Karaca, Halit
    Berk, Veli
    Ozkan, Metin
    Sivgin, Serdar
    Eser, Bulent
    Cetin, Mustafa
    Elmali, Ferhan
    MEDICAL ONCOLOGY, 2014, 31 (03)
  • [44] Surgical resection of a well-differentiated inflammatory liposarcoma of the middle mediastinum: a case report
    Edagawa, Makoto
    Haratake, Naoki
    Shimamatsu, Shinichiro
    Toyozawa, Ryo
    Nosaki, Kaname
    Hirai, Fumihiko
    Yamaguchi, Masafumi
    Taguchi, Kenichi
    Kaneko, Koichiro
    Seto, Takashi
    Takenoyama, Mitsuhiro
    Ichinose, Yukito
    JOURNAL OF THORACIC DISEASE, 2017, 9 (08) : E689 - E693
  • [45] Rare Metastases of Well-Differentiated Thyroid Cancers: A Systematic Review
    Madani, Amin
    Jozaghi, Yelda
    Tabah, Roger
    How, Jacques
    Mitmaker, Elliot
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (02) : 460 - 466
  • [46] Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases
    Body, J.-J.
    Lichinitser, M.
    Tjulandin, S.
    Garnero, P.
    Bergstroem, B.
    ANNALS OF ONCOLOGY, 2007, 18 (07) : 1165 - 1171
  • [47] Atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma in patients aged ≤ 40 years: a study of 116 patients
    Waters, Rebecca
    Horvai, Andrew
    Greipp, Patricia
    John, Ivy
    Demicco, Elizabeth G.
    Dickson, Brendan C.
    Tanas, Munir R.
    Larsen, Brandon T.
    Din, Nasir Ud
    Creytens, David H.
    Bahrami, Armita
    Doyle, Leona A.
    Jo, Vickie Y.
    Al-Ibraheemi, Alyaa
    Thway, Khin
    Jenkins, Sarah M.
    Siontis, Brittany
    Folpe, Andrew
    Fritchie, Karen
    HISTOPATHOLOGY, 2019, 75 (06) : 833 - 842
  • [48] EORTC QLQ-BM22 Quality of Life Evaluation and Pain Outcome in Patients with Bone Metastases from Breast Cancer Treated with Zoledronic Acid
    Yeh, Dah-Cherng
    Chen, Dar-Ren
    Chao, Tsu-Yi
    Chen, Shin-Cheh
    Wang, Hwei-Chung
    Rau, Kun-Ming
    Feng, Yin-Hsun
    Chang, Yuan-Ching
    Lee, Kuan-Der
    Ou-Yang, Fu
    Kuo, Wen-Hung
    Chang, King-Jen
    Lin, Yung-Chang
    Tseng, Ling-Ming
    Hou, Ming-Feng
    IN VIVO, 2014, 28 (05): : 1001 - 1004
  • [49] Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid
    Saad, Fred
    Segal, Scott
    Eastham, James
    EUROPEAN UROLOGY, 2014, 65 (01) : 146 - 153
  • [50] Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma
    Yasuda, Yosuke
    Fujii, Yasuhisa
    Yuasa, Takeshi
    Kitsukawa, Shinichi
    Urakami, Shinji
    Yamamoto, Shinya
    Yonese, Junji
    Takahashi, Shunji
    Fukui, Iwao
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (05) : 877 - 883